Source: http://www.google.com/patents/US6635222?dq=7,134,016
Timestamp: 2014-12-22 13:00:58
Document Index: 379324980

Matched Legal Cases: ['art 2', 'art.18', 'art.56', 'art 2', 'art.76', 'art.105', 'art.106', 'art.164', 'art 1', 'art 2']

Patent US6635222 - Method of sterilizing products - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsA method for sterilizing products to inactivate biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites is disclosed. The method involves irradiating the product at a low dose rate from about 0.1 kGy/hr. to about 3.0 kGy/hr. for a period of time sufficient to sterilize...http://www.google.com/patents/US6635222?utm_source=gb-gplus-sharePatent US6635222 - Method of sterilizing productsAdvanced Patent SearchPublication numberUS6635222 B2Publication typeGrantApplication numberUS 09/985,606Publication dateOct 21, 2003Filing dateNov 5, 2001Priority dateJul 22, 1993Fee statusLapsedAlso published asCA2167528A1, CA2167528C, DE69432351D1, DE69432351T2, EP0710124A1, EP0710124B1, US5362442, US6171549, US6346216, US20030059339, US20030143107, US20080176306, WO1995003071A1Publication number09985606, 985606, US 6635222 B2, US 6635222B2, US-B2-6635222, US6635222 B2, US6635222B2InventorsRandall S. KentOriginal AssigneeClearant, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (85), Non-Patent Citations (186), Referenced by (6), Classifications (9), Legal Events (5) External Links: USPTO, USPTO Assignment, EspacenetMethod of sterilizing productsUS 6635222 B2Abstract A method for sterilizing products to inactivate biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites is disclosed. The method involves irradiating the product at a low dose rate from about 0.1 kGy/hr. to about 3.0 kGy/hr. for a period of time sufficient to sterilize the product. The method does not destroy sensitive materials such as blood and blood components. Further, the method does not require pre-treatment of the product such as freezing, filtration or the addition of chemical sensitizers.
What I claim as my invention is: 1. A method for sterilizing a biological product comprising irradiating the product with gamma irradiation at a rate of from about 0.25 kGy/hr. to about 20 kGy/hr. for a period of time sufficient to sterilize the product, wherein said biological product contains at least one biological material selected from the group consisting of: dextrose, antibodies, IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII, Factor IX, pharmaceuticals, nucleic acids, body fluids, saliva, cerebral spinal fluid, liposomes, glucose, cell culture media, fetal bovine serum, bone marrow and organs.
2. A method according to claim 1, wherein said irradiation is provided at a rate of from about 0.5 kGy/hr. to about 1.5 kGy/hr.
3. A method according to claim 1, wherein said irradiation is provided at a rate of from about 0.5 kGy/hr. to about 1.0 kGy/hr.
4. A method according to claim 1, wherein said product contains dextrose.
5. A method according to claim 1, wherein said biological product is an antibody.
6. A method according to claim 1, wherein said product is in lyophilized form.
7. A method according to claim 6, wherein said product is selected from the group consisting of IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII and Factor IX.
8. A method according to claim 1, wherein said product is selected from the group consisting of IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII and Factor IX.
9. A method for sterilizing a biological product comprising irradiating the product at ambient temperature or below with gamma irradiation at a rate of from about 0.1 kGy/hr. to about 3.0 kGy/hr. for a period of time sufficient to sterilize the product, wherein said biological product contains at least one biological material selected from the group consisting of: dextrose, antibodies, IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII, Factor IX, pharmaceuticals, nucleic acids, body fluids, saliva, cerebral spinal fluid, liposomes, glucose, cell culture media, fetal bovine serum, bone marrow and organs.
10. A method for sterilizing a biological product comprising irradiating the product with gamma irradiation at a rate of from about 0.1 kGy/hr. to about 3.0 kGy/hr for a period of time sufficient to sterilize the product, wherein said biological product contains at least one biological material selected from the group consist of: dextrose, antibodies, IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII, Factor IX, pharmaceuticals, nucleic acids, body fluids, saliva, cerebral spinal fluid, liposomes, glucose, cell culture media, fetal bovine serum, bone marrow and organs.
11. A method for sterilizing a biological product comprising irradiating the product with gamma irradiation at a rate of from about 0.1 kGy/hr. to about 3.0 kGy/hr. for a period of time greater than 10 hours, wherein said biological product contains at least one biological material selected from the group consisting of: dextrose, antibodies, IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII, Factor IX, pharmaceuticals, nucleic adds, body fluids, saliva, cerebral spinal fluid, liposomes, glucose, cell culture media, fetal bovine serum, bone marrow and organs.
12. The method according to one of claims 9, 10 or 11, wherein said irradiation is provided at a rate of from about 0.25 kGy/hr. to about 2.0 kGy/hr.
13. The method according to one of claims 9, 10 or 11, wherein said irradiation is provided at a rate of from about 0.5 kGy/hr. to about 1.5 kGy/hr.
14. The method according to one of claims 9, 10 or 11, wherein said irradiation is provided at a rate of from about 0.5 kGy/hr. to about 1.0 kGy/hr.
15. The method according to one of claims 9, 10 or 11, wherein said biological product comprises dextrose.
16. The method according to claim one of claims 9, 10 or 11, wherein said biological product is an antibody.
17. The method according to one of claims 9, 10 or 11, wherein said biological product is in lyophilized form.
18. The method according to one of claim 17, wherein said biological product is selected from the group consisting of IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII and Factor IX.
19. The method according to one of claims 9, 10 or 11, wherein said biological product is selected from the group consisting of IgG, albumin, alpha 1 proteinase inhibitor, fibrinogen, Factor VII, Factor VIII and Factor IX.
This application is a continuation of Ser. No. 09/570,929, filed May 15, 2000, and now U.S. Pat. No. 6,346,216, which is a continuation of Ser. No. 08/573,149, filed Dec. 15, 1995, now U.S. Pat. No. 6,171,549, which is a continuation-in-part of PCT/CA94/00401 filed Jul. 22,1994, which is a continuation-in-part of Ser. No. 08/095,698, filed Jul. 22, 1993 now U.S. Pat. No. 5,362,442.
FIELD OF THE INVENTION The present invention relates to a method for sterilizing products to inactivate biological contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites.
BACKGROUND OF THE INVENTION Several products that are prepared for human, veterinary or experimental use may contain unwanted and potentially dangerous contaminants such as viruses, bacteria, yeasts, molds, mycoplasmas and parasites. Consequently, it is of utmost importance that any biologically active contaminant in the product be inactivated before the product is used. This is especially critical when the product is to be administered directly to a patient, for example in blood transfusions, organ transplants and other forms of human therapies. This is also critical for various biotechnology products which are grown in media which contain various types of plasma and which may be subject to mycoplasma or other viral contaminants.
Previously, most procedures have involved methods that screen or test products for a particular contaminant rather than removal or inactivation of the contaminant from the product. Products that test positive for a contaminant are merely not used. Examples of screening procedures include the testing for a particular virus in human blood from blood donors. However, such procedures are not always reliable and are not able to detect the presence of viruses in very low numbers. This reduces the value or certainty of the test in view of the consequences associated with a false negative result. False negative results can be life threatening in certain cases, for example in the case of Acquired Immune Deficiency Syndrome (AIDS). Furthermore, in some instances it can take weeks, if not months, to determine whether or not the product is contaminated.
More recent efforts have focused on methods to remove or inactivate contaminants in the products. Such methods include heat treating, filtration and the addition of chemical inactivants or sensitizers to the product. Heat treatment requires that the product be heated to approximately 60� C. for about 70 hours which can be damaging to sensitive products. Heat inactivation can destroy up to 50% of the biological activity of the product. Filtration involves filtering the product in order to physically remove contaminants. Unfortunately this method may also remove products that have a high molecular weight. Further, in certain cases small viruses may not be removed by the filter because of the larger molecular structure of the product. The procedure of chemical sensitization involves the addition of noxious agents which bind to the DNA/RNA of the virus and which are activated either by UV or ionizing radiation to produce free radicals which break the chemical bonds in the backbone of the DNA/RNA of the virus or complex it in such a way that the virus can no longer replicate. This procedure requires that unbound sensitizer is washed from cellular products since the sensitizers are toxic, if not mutagenic or carcinogenic, and can not be administered to a patient.
Irradiating a product with gamma irradiation is another method of sterilizing a product. Gamma irradiation is effective in destroying viruses and bacteria when given in high total doses. (Keathly, J. D. Et al.; Is There Life after Irradiation? Part 2; BioPharm July-August, 1993, and Leitman, Susan F.; Use of Blood Cell Irradiation in the Prevention of Post Transfusion Graft-vs-Host Disease; Transfusion Science 10:219-239, 1989). However, the published literature in this area teaches that gamma irradiation can be damaging to radiation sensitive products such as blood. In particular, it has been shown that high radiation doses are injurious to red cells, platelets and granulocytes (Leitman, ibid). Van Duzer, in U.S. Pat. No. 4,620,908 discloses that the product must be frozen prior to irradiation in order to maintain the viability of a protein product. Van Duzer concludes that:
�If the gamma irradiation were applied while the protein material was at, for example, ambient temperature, the material would be also completely destroyed, that is the activity of the material would be rendered so low as to be virtually ineffective.�
Unfortunately, many sensitive biologicals, such as blood, would lose viability and activity if subjected to freezing for irradiation purposes and then thawing prior to administration to a patient.
SUMMARY OF THE INVENTION In view of the above, there is a need to provide a method of sterilizing products that is effective in removing biological contaminants while at the same time having no adverse effect on the product. The present invention has shown that if the irradiation is delivered at a low dose rate, then sterilization can be achieved without harming the product. No prior references have taught or suggested that applying gamma irradiation at a low dose rate can overcome the problems admitted in the prior references.
Accordingly, the present invention provides a method for sterilizing a product comprising irradiating the product with gamma irradiation at a rate from about 0.1 kGy/hr. to about 3.0 kGy/hr. for a period of time sufficient to sterilize the product.
The rate of irradiation can be specifically from about 0.25 kGy/hr. to about 2.0 kGy/hr., more specifically from about 0.5 kGy/hr. to about 1.5 kGy/hr. and even more specifically from about 0.5 kGy/hr. to about 1.0 kGy/hr.
The term �sterilize� as used in the present application generally means to inactivate any biological contaminant present in the product.
The length of time of irradiation or the total dose of irradiation delivered will depend on the bioburden of the product, the nature of the contaminant and the nature of the product.
Higher doses of irradiation are required to inactivate viruses as compared to bacteria. For example, using the dose rates of the present invention, one may use an irradiation time of greater than 10 hours to eliminate viral contamination in contrast to an irradiation time of only 45 minutes to remove bacterial contamination.
The process according to the present invention can be carried out at ambient temperature and does not require the heating, freezing, filtration or chemical treatment of the product before the process is carried out. This offers another significant advantage of the present process as it avoids some of the extra treatment steps of the prior art processes.
Certain products, such as blood, may be diluted prior to irradiation. Diluting the product may serve to reduce degradation of the product during irradiation. The choice of diluent depends on the nature of the product to be irradiated. For example, when irradiating blood cells one would choose a physiologically acceptable diluent such as citrate phosphate dextrose.
In cases where living cells (such as blood cells) are to be irradiated, a scavenger may be added to bind free radicals and other materials that are toxic to cells. A suitable scavenger is ethanol.
The efficacy of the method of the present invention is contrary to what others skilled in this area have observed or predicted. (U.S. Pat. No. 4,620,908 and Susan Leitman, ibid). The method provides a method of irradiating products that is not harmful to the product itself. In particular, the method of the present invention can effectively sterilize a product as fragile as blood without destroying the viability of the cells contained therein. Consequently the method of the present invention offers a significant technical and scientific advancement to the sterilization field. The method also provides an invaluable service to health care and the general public by providing a method to produce safe and sterile products for human use. This is especially critical in light of the spread of viral diseases such as AIDS and hepatitis through the transfusion of contaminated blood and blood products.
DESCRIPTION OF PREFERRED EMBODIMENTS The following examples are provided in order to illustrate the method of the present invention and are not meant to limit the scope of the invention.
EXAMPLE 1 Sterilization of Blood A 200 ml bag of one day old packed red blood cells was used. Ethanol was added to the cells in order to achieve a final ethanol concentration of 0.01% v/v. The red blood cells were diluted by a factor of one in ten using a modified Citrate Phosphate Dextrose (CPD) solution having a pH of about 6.4 to 6.7 and having the following composition in a total volume of 500 ml:
Sodium Monobasic Phosphate
Sodium Dibasic Phosphate
The cells were irradiated in a commercial size gamma irradiator which contained a cobalt 60 source rack. Irradiation was done off carrier in an unprotected box. The cells were irradiated for twenty four hours at a rate of approximately 1 kGy/hr. After the irradiation period the red blood cells were examined visually and were found to be viable, having a brilliant red colour. A control sample, consisting of packed red blood cells that were not diluted with the above-described CPD solution, was not viable after irradiation.
Four days after the irradiation procedure, the diluted cells were tested for levels of various blood components and the results are shown in Table 1. The control sample consisted of blood from the same bag as the test sample but it did not undergo irradiation. Table 1 illustrates that dilution and irradiation of human blood cells did not significantly alter the white blood cell count. The platelet count and hematocrit values were slightly lower than the control; however, these values are still within the range that is seen in normal adult blood. The level of hemoglobin was higher than in the control indicating that some red blood cells did lyse during the procedure. This is also evidenced by the lower red blood cell count. Nevertheless, contrary to what has been previously published, up to 25 kGy of radiation did not destroy the components of blood by the present procedure. The cells were also counted and found to be viable after 25 kGy of gamma irradiation delivered at a low dose rate of 1 kGy/hr.
K/mm3 4.8
K/mm3 Red Blood Cells
Mi/mm3 7.2
Mi/mm3 Hemoglobin
k/mm3 120
k/mm3 EXAMPLE 2 Sterilization of Dextrose Dextrose (or glucose) containing solutions are used in the treatment of carbohydrate and fluid depletion, in the treatment of hypoglycaemia, as a plasma expander, in renal dialysis and to counteract hepatotoxins (The Merck Index, Eleventh Edition; Merck & Co. Inc., 1989 and Martindale's Extra Pharmacopecia p. 1,265). Dextrose is also the preferred source of carbohydrate in parental nutrition regimens (The Merck Index, Eleventh Edition; Merck & Co. Inc., 1989 and Martindale's Extra Pharmacopecia p. 1,265). In all of the above applications, the dextrose must be sterilized before use. Sterilization of dextrose containing products is generally done by heat sterilization or autoclaving. Unfortunately, these methods have been reported to degrade or caramelize dextrose containing solutions resulting in a colour change in the solution (Martindale's Extra Pharmacopecia p. 1,265). Gamma irradiation of glucose has also been reported to decompose glucose containing solutions (Kawakishi et al.; Radiation-Induced Degradation of D-glucose in Anaerobic Condition. Agric. Biol. Chem. June, 1977). Therefore, there is a need for a method that can sterilize dextrose containing products that does not degrade the product itself. In view of the problems of the prior art, a dextrose solution was treated according to the method of the present invention as follows.
A 5% dextrose solution was irradiated for 24 hours, at a rate of approximately 1 kGy/hr. After irradiation the product was tested and it was found that there was no visible light spectrum change as compared to the non-irradiated control. Therefore, the present method can be useful in sterilizing products that contain dextrose.
In addition to the above experiment, fresh solutions of 5% and 50% dextrose were irradiated to 25 kGy over 36 hours at ambient temperature. The results were similar to those described above. In addition, UV/VIS scans were obtained and demonstrated a complete absence of the peak at 283.4 nm for �furfurals� as per U.S.P. In contrast, dextrose samples sterilized using an autoclave contain the 283.4 furfural peak. �Furfurals� are carcinogenic.
EXAMPLE 3 Sterilization of Human Serum Albumin Normal Human Serum Albumin was irradiated as a 25% salt-poor solution to a total dose of 25 kGy over 36 hours using a Gammacell 220 (Co60 is the gamma ray source in this instrument). The temperature was not controlled during the irradiation but it is estimated that the container holding the albumin solution was approximately 23� C. The results of HPLC analysis are given in Table 2.
IRRADIATED (%)
NTU (must be >20)
As the results demonstrate, Normal Human Serum Albumin can safely be irradiated to 25 kGy (at a rate of approximately 0.7 kGy/hr.) at room temperature without adversely affecting the essential properties of the protein. This has not been demonstrated before. All other attempts at irradiating serum albumin require that it be irradiated in the frozen stage. This adds to the cost and difficulty of doing the irradiation.
EXAMPLE 4 Normal human blood from a healthy donor was taken in a heparinized tube, washed three times with standard CPD solution, then diluted 1:20 with CPD containing 0.01% v/v Ethanol. This latter solution of CPD with 0.01% v/v Ethanol is called SCPD. Two ml aliquots were then placed in 10 ml plastic test tubes and irradiated to different doses up to 26 kGy over 36 hours at room temperature. There was no haemolysis and the cells appeared intact if somewhat large and slightly irregular in shape. The results of three separate experiments are reported in Table 3.
RBC1 HGB2 HCT3 MCV4 MCH5 MCHC6 RDW7 FLAGS
12 kGy 1
1 + Anisocytosis
3 + Macrocytocis
16 kGy
2 + Anisocytosis
244 .125
26 kGy 1
*Experiment 1 and Experiment 2 1Red Blood Cell Count: Cells � 1012/liter 2Hemoglobin: grams/liter 3Hematocrit 4Mean Corpuscular Volume: Femtoliters 5Mean Corpuscular hemoglobin: picograms 6Mean Corpuscular hemoglobin Concentration: grams/liter The cells were easily put into suspension and reconstituted in fresh buffer.
The following three experiments (Examples 5, 6 and 7) were conducted in order to determine the efficacy of the method when treating HIV-contaminated blood. In each Example the cells were similarly treated. In these experiments, the cells were gently agitated after 12, 16 and 24 hours of irradiation. Further, in the third experiment, (Example 7), the cells were placed in T25 flasks to provide greater surface area and reduce the concentration due to settling in the bottom of the centrifuge tubes. In each case, the cells were irradiated at a dose rate of approximately 0.7 kGy/hr.
EXAMPLE 5 Sterilization of HIV-containing Blood The following experiment was undertaken with the following specific objectives:
1. To evaluate the toxicity of the process towards red blood cells (RBCs).
2. To evaluate the anti-retroviral activity of the process.
Procedure Initially, 2 ml of anticoagulated-blood was obtained from an HIV-seronegative donor. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 40 ml of the SCPD buffer, and distributed into plastic tubes in 2 ml aliquots, with 16 separate aliquots being retained for further manipulation. For 8 of these tubes, an aliquot of HTLV-IIIB was added. This is a laboratory strain of the HIV virus and 100 tissue culture infective doses (TCID) were added to each of the tubes to be infected. For the remaining 8 tubes, a �mock� infection was performed, by adding a small amount of non-infectious laboratory buffer, phosphate buffered saline (PBS). Four infected and four non-infected tubes were subjected to the process. For comparison, the remaining 8 tubes (four infected and four non-infected) were handled in an identical manner, except that they were not subjected to the process.
It should be stated that at the beginning of the study, a separate aliquot of blood was obtained from the donor. This was processed in the clinical hematology laboratory and a complete hemogram was performed. These baseline results were compared to repeat testing on the study aliquots, which included evaluation of four processed and four unprocessed samples, all of which were not infected with HIV.
An aliquot of 0.5 ml of each of the infected study samples was inoculated on mononuclear cells (MCs) which had been obtained three days earlier. These cells had been suspended in RPMI culture medium, with 10% fetal calf serum and other additives (penicillin, streptomycin, glutamine and HEPES buffer) along with 1 ug/ml PHA-P. At the same time as this inoculation, the cells were resuspended in fresh medium with rIL-2 (20 U/ml). The cultures were maintained for 7 days. Twice weekly, a portion of the culture medium was harvested for the measurement of HIV p24 antigen levels (commercial ELISA kit, Coulter Electronics, Hialeah, Fla.) for the measurement of viral growth.
A separate aliquot of the eight infected study samples was used for viral titration experiments. Briefly, serial four-fold dilutions of the virus-containing fluids (ranging from 1:16 to 1:65,536) were inoculated in triplicate in 96-well flat-bottom tissue culture plates. PHA-stimulated MCs were added to each well (4 million cells in 2 ml culture medium, with IL-2). An aliquot of the supernatant from each culture well was harvested twice weekly for the measurement of HIV p24 antigen levels. A well was scored as �positive� if the HIV p24 antigen value was >30 pg/ml.
The viral titer was calculated according to the Spearman-Karber method (see ACTG virology protocol manual) using the following equation:
M=xk+d[0.5−(1/n)r] M: titer (in log 4)
xk: dose of highest dilution
d: space between dilutions
n: number of wells per dilution
r: sum of total number of wells
Results Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 4.
Sample/Number
Unprocessed-1
Unprocessed-2
Unprocessed-3
Unprocessed-4
Processed-2
Processed-3
Processed-4
The abbreviations used in Table 4 are explained under Table 3.
As described above, HIV cultures were established using 0.5 ml aliquots of unprocessed and processed study samples. P24 antigen levels (pg/ml) from the study samples on day 4 and day 7 of culture are shown in Table 5.
p24-DAY 4
p24-DAY 7
Finally, one unprocessed sample and one processed sample were selected for the performance of direct viral titration without culture. The results are shown in Table 6.
Titer (log 10 ml)
The red blood cells were minimally affected by the process, although some reproducible macrocytosis was observed. Although on co-culturing of processed samples, there appeared to be some residual live virus, this was not confirmed by direct titration experiments.
EXAMPLE 6 The objective of this experiment was to evaluate the toxicity of the process towards red blood cells in a comprehensive manner.
Methods For this experiment, 1 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first experiment. The blood was centrifuged and the plasma was removed. The remaining cell pellet was resuspended in 10 ml of the CPD buffer and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 20 ml of the SCPD buffer, and distributed into plastic tubes in 2 ml aliquots, with all 10 aliquots being retained for further manipulation. Eight tubes were subjected to the process, while the final two tubes were retained as control, unprocessed tubes. After the processing, all ten tubes were centrifuged, and the resulting pellet was resuspended in 100 ul buffer. A complete hemogram was performed on these reconcentrated study samples.
As in the first experiment, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, more direct comparisons with the baseline sample could be undertaken than were possible in our earlier experiment.
Results Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 7. The abbreviations used in Table 7 are defined in Table 3.
152 94.9
Processed-5
Processed-6
Processed-7
Processed-8
There was macrocytosis of the cells which was present in all the processed samples. Comparable hemoglobin levels were measured in the unprocessed and processed samples. The absolute values were appropriate for the residual dilution. The red blood cells are preserved.
EXAMPLE 7 The objective of this experiment was to verify and expand upon the results obtained in Example 6.
Methods For this experiment 5 ml of anticoagulated blood was obtained from the same HIV-seronegative donor as in the first two experiments. The blood was centrifuged, and the plasma was removed. The remaining cell pellet was resuspended in 100 ml of the CPD buffer, and centrifuged. This washing process was repeated a total of three times. The final pellet was resuspended in 100 ml of the SCPD buffer, and distributed in 25 ml aliquots, in T25 tissue culture flasks, with all four aliquots been retained for further manipulation. Two flasks were subject to the process, while the other two were retained as control, unprocessed flasks. After the processing, the contents of each of the flasks was observed and a visual determination of the cells capacity to absorb oxygen (turning a brighter red on exposure to ambient air) was made. Following this, the contents of the flasks were aspirated and centrifuged, with the residual pellet resuspended in a small volume of buffer. A complete hemogram was performed on these re-concentrated study samples.
As in Examples 5 and 6, a separate aliquot of blood was obtained from the donor when the study sample was taken. A complete hemogram was performed on this baseline sample. As the study samples were re-concentrated to 33-50% of their original state, direct caparisons of a number of specific parameters would be possible with the baseline sample.
Results On visual inspection, there were no appreciable differences between the processed and unprocessed study samples. Specifically, there appeared to be a uniform distribution of well suspended cells. On exposure to ambient air, the contents of all flasks became somewhat brighter red. No specific quantitative measurements of oxygenation were made.
Red blood cell parameters for the baseline sample as well as for the unprocessed and processed study samples are shown in Table 8. The abbreviations used in Table 8 are defined under Table 3.
153 95.0
This experiment was designed to more closely approximate conditions of red blood cells to be transfused into a patient, and was consequently conducted at higher volumes. On a preliminary basis, it does not appear that the process impairs the red blood cells' ability to carry oxygen, although this should be measured more formally. Interestingly, in this experiment, there was no difference in cell size between the processed and unprocessed samples, both being large compared to baseline. Comparable haemoglobin levels were measured in all the study samples.
EXAMPLE 8 In this experiment, Immunoglobulin G (IgG) was irradiated in lyophilized form.
Method The IgG was irradiated as a powder to a total dose of 25 kGy using a Gammacell 220. The temperature of the container holding the material was approximately 23� C. The dose rate was 0.72 kGy/hr.
Results The results of HPLC analysis of IgG are given in Table 9. As the results demonstrate, the product appears to be unaffected after being irradiated to a dose of 25 kGy at room temperature when the irradiation is delivered at a rate of approximately 0.7 kGy/hr. This has not been previously demonstrated.
Polymer (must be >2%)
The results presented by Gergely, et al. using freeze dried IgG showed that a portion of the protein was insoluble after an irradiation dose of 12 kGy to 25 kGy at standard irradiation dose rates. (Gergely, J., Medgyesi, G. A., Igali, A. Studies of Gamma-Ray-Irradiated Human Immunoglobulin G. SM-92/12 I.A.E.A.). These results would indicate a change/degradation of the protein. In contrast, using the present method at a dose rate of approximately 0.7 kGy/hr., none of the protein was insoluble. This would indicate that little or no change or degradation of the protein occurred. Further, Gergely et al. found that a liquid formulation of human IgG lost all of its activity after irradiation. In studies using the present method on intravenous immunoglobulin (IVIG) in liquid form, it was shown that greater than 70% of a specific antibody in hyperimmune IVIG was retained.
EXAMPLE 9 In this experiment, alpha 1 proteinase inhibitor and fibrinogen were irradiated in lyophilized form.
Method The samples were placed in a Gammacell 220 and irradiated according to the present process to a total dose of 25 kGy. Samples were then returned to the laboratory for analysis. The dose rate was 0.72 kGy/hr.
Results The alpha 1 proteinase inhibitor, both treated and control, were 40% of a standard normal pooled plasma sample. The Mancini radial immunodiffusion technique was used as the assay.
The topical fibrinogen complex vials were reconstituted in 10 ml of water. Protamine sulphate at a concentration 10 mg/ml was added to the samples. There was instant formation of monomer in all three preparations.
EXAMPLE 10 In this experiment, Factors VII, VIII and IX were irradiated in lyophilized form.
Method The samples were placed in a Gammacell 220 and irradiated to various total doses at a dose rate of approximately 1 kGy/hr.
Results Factor VII retained 67% activity at 20 kGy and 75% at 10 kGy. Factor VIII retained 77% activity at 20 kGy and 88% at 10 kGy. Similarly Factor IX showed an activity level of 70% at 20 kGy and 80% at 10 kGy.
Analysis Excellent results were found for the three Factors. To our knowledge, no one has been able to achieve these results by irradiating the Factors at ambient temperature to such a high dose of radiation with such little loss of activity. This is in direct contrast with the results of Kitchen et. al. (Kitchen, A. D. Mann, G. F., Harrison, J. F., Zuckerman, A. J. Effect of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation Proteins. Vox Sang 1989, 56:223-229) who found that �the irradiation of lyophilized concentrates is not a viable procedure�. Similarly, Hiemstra et. al., (Hiemstra, H., Tersmette, M., Vos., A. H. V., Over, J., van Berkel, M. P. and de Bree, H. Inactivation of human immuondeficiency virus by gamma radiation and its effect on plasma and coagulation factors. Transfusion, 1991, 31:32-39) also concluded that �Gamma radiation must be disregarded as a method for the sterilization of plasma and plasma-derived products, because of the low reduction of virus infectivity at radiation doses that still give acceptable recovery of biologic activity of plasma components.�
EXAMPLE 11 In this experiment, red blood cells were irradiated at a dose rate of 0.5 kGy/hr. for periods of time ranging from 7 � to 90 minutes in order to remove bacterial contaminants.
Method Red blood cells were collected from a healthy donor in EDTA, washed 3 times with CPD solution and resuspended in CPD to provide a 1:20 dilution based on the original blood volume. The cell suspension was then subdivided into 14 tubes. To seven of the tubes approximately 1.0�104 Staphylococcus epidermidis were added. The cells were placed on ice for transport to the irradiation facility. All of the samples were placed in the chamber at ambient temperature and irradiated at 0.5 kGy/hr. for periods of time to give total doses of 0.0625, 0.125, 0.250, 0.375, 0.500 and 0.750 kGy respectively. The samples were removed and agitated at each time point and placed on ice for transport either to the microbiology lab or to the hematology lab for analysis.
Results The results of the microbiology assays are given in Table 10.
RADIATION DOSE (kGy)
0 92200
Thus a dose of 0.75 kGy provides a 4.5 log10 reduction in bacterial survivors. This represents a significant safety factor for blood. Further, the D10 value is approximately 0.125 kGy which corresponds well with the values reported in the literature for similar species of staphylococcus (B. A. Bridges, The effect of N-Ethylmaleimide on the radiation sensitivity of bacteria. J. Gen. Microbiol. 1961, (26) 467-472 and G. P. Jacobs and N. Sadeh, Radiosensitization of Staphylococcus aureus by p-hydroxybenzoic acid. Int. J. Radiat. Biol; 1982, 41, 351-356).
In order to demonstrate that the red blood cells remained viable after the irradiation process, the following parameters were determined for the cells; WBC, Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils. These determinations merely enumerated the number of cells present. All nucleated cells would, of course, be inactivated by the radiation dose delivered. The other red blood cell parameters monitored are listed in Table 11. The Methaemoglobin value was unchanged from that of the controls even after a radiation dose of 0.75 kGy. This experiment demonstrates that red blood cells can be safely irradiated by the present method to a dose of 0.75 kGy at room temperature with no loss of cell function.
Red Blood Cell Values as a Function of Radiation Dose Received
METHgB
EXAMPLE 12 This experiment was conducted using the method in Example 11 to confirm the findings of Example 11 and to expand upon some of the parameters measured. The results of this experiment are given in Table 12.
Results Red Blood Cell Values as a Function of Radiation Dose Received
% MET
p60 (mm Hg)
nd = not done The uncertainty with the methaemoglobin levels is ⊥ 2%; with p50 it is ⊥ 4% (95% confidence). These results confirm the previous results and indicate that indeed, red blood cells can be irradiated to a dose sufficient to provide 4.5 log10 (reduction in bacteria count.
It is contemplated that future experiments will provide similar results for platelets. Thus with little or no additional manipulation, and without the addition of extraneous materials, red blood cells can be treated by the present process to provide a bacteriologically safe product, thus further reducing the risk of untoward reactions in recipients.
As evidenced by all of the above experiments, the present invention demonstrates that irradiating a product at a low dose rate from about 0.1 kGy/hr. to about 3.0 kGy/hr. is effective in sterilizing the product without adversely affecting the product itself.
While the Examples relate to specific embodiments of the method of the present invention, one skilled in the art will realize that the total time of irradiation will depend on the type of contaminant, the bioburden of the product and the nature of the product. For example, bacterial contaminants can be eliminated with very little irradiation time while viral inactivation requires a longer irradiation time. Further, extremely sensitive products, such as blood, are preferably diluted in a physiologically acceptable diluent prior to irradiation.
It is to be appreciated that the method of the present invention can be used to treat an extremely wide variety of products that require sterilization. The fact that the present method has proven effective in blood which is a fragile biological material makes it reasonable to predict that the method can be used on many similarly sensitive products. Examples of other products that may be treated include pharmaceuticals, proteins, nucleic acids, blood components, body fluids (such as cerebral spinal fluid, saliva), liposomes, glucose containing products, cell culture media, fetal bovine serum, bone marrow, organs, foods and cosmetics such as shampoos, lotions and creams. The products may be irradiated in various forms, including, solid, liquid and lyophilized forms.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2832689Jan 24, 1952Apr 29, 1958Research CorpPreservation of organic materials by irradiationUS2920969Aug 25, 1954Jan 12, 1960Gen ElectricMethod and means for irradiating foodsUS2962380Oct 8, 1956Nov 29, 1960Research CorpRadiation sterilization of fluid food productsUS3620944Mar 12, 1968Nov 16, 1971Osaka PrefectureProcess of purifying water by irradiating itUS3743480Apr 9, 1971Jul 3, 1973Allied ChemSterilization of biological fluidsUS3779706Oct 4, 1971Dec 18, 1973Energy Sciences IncProcess for bulk sterilization, minimizing chemical and physical damageUS4136094Aug 31, 1977Jan 23, 1979The Regents Of The University Of MinnesotaSilica treatment, ion exchangingUS4251437Oct 26, 1979Feb 17, 1981Nordisk InsulinlaboratoriumControlled temperature thawing, precipitation, redissolvingUS4282863Jul 20, 1978Aug 11, 1981Beigler Myron AMethods of preparing and using intravenous nutrient compositionsUS4330626Mar 19, 1980May 18, 1982The Enzyme Center, Inc.Gamma irradiation of jackbeans prior to grindingUS4336247Jul 14, 1980Jun 22, 1982Eriksen Arthur EAscorbic acid added to freeze dried musselsUS4370264Sep 8, 1981Jan 25, 1983Biotest-Serum-Institut GmbhIrradiation with uv light, treatment with b-propiolactone, adsorption onto colloidal silicaUS4409105Nov 20, 1981Oct 11, 1983Asahi Kasei Kogyo Kabushiki KaishaDried, sterilized, gamma-globulin-fixed column and a process for preparing the sameUS4472840Sep 30, 1982Sep 25, 1984Jefferies Steven REomplex of collagen, bone particles, and proteinUS4620908Jun 18, 1984Nov 4, 1986Biocell Laboratories, Inc.Method for destroying microbial contamination in protein materialsUS4784850Sep 4, 1985Nov 15, 1988Mutzarei MaabarotProcess for preparing antibodies against E. Coli K-99 antigen from bovine milkUS4798611Oct 14, 1986Jan 17, 1989Hancock Jaffe LaboratoriesProsthetics, crosslinkingUS4865602Nov 6, 1986Sep 12, 1989Collagen CorporationGamma irradiation of collagen/mineral mixturesUS4931361Nov 18, 1988Jun 5, 1990California Institute Of TechnologyCryoprotective reagents in freeze-drying membranesUS4933145Jun 3, 1988Jun 12, 1990Terumo Kabushiki KaishaAdding organic acid to adjust phUS4946648Sep 7, 1988Aug 7, 1990Biotest Pharma GmbhMethod of sterilizing plasma or plasma fractionsUS4963356Apr 20, 1987Oct 16, 1990Minnesota Mining And Manufacturing CompanyStable antigenic extracts methodsUS5000951Jan 18, 1990Mar 19, 1991Diamond Scientific CompanyMultivalent canine distemper virus vaccineUS5012503Nov 4, 1987Apr 30, 1991Sumitomo Bakelite Company, Ltd.Freezing, vacuum dehydrationUS5044091Apr 16, 1990Sep 3, 1991Sankyo Company, LimitedFrozen first and second liquid freeze dried togetherUS5106619Jan 10, 1990Apr 21, 1992Diamond Scientific Co.Preparation of inactivated viral vaccinesUS5134295Mar 29, 1991Jul 28, 1992Waelischmiller HansIrradiation apparatusUS5185371Mar 13, 1990Feb 9, 1993University Of Southern CaliforniaMethod for disinfecting red blood cellsUS5226065May 10, 1991Jul 6, 1993Stericycle, Inc.Device for disinfecting medical materialsUS5283034Mar 26, 1992Feb 1, 1994Applied Immune Sciences, Inc.Stabilization of sterilized surfaces for research and medical useUS5362442Jul 22, 1993Nov 8, 19942920913 Canada Inc.Method for sterilizing products with gamma radiationUS5418130Jul 13, 1993May 23, 1995Cryopharm CorporationPhosphonium or ammonium halo-psoralenUS5460962Jan 4, 1994Oct 24, 1995Organogenesis Inc.Peracetic acid sterilization of collagen or collagenous tissueUS5510122Sep 28, 1994Apr 23, 1996The Research Foundation Of State University Of New YorkCollection, then sterilization with chlorhexidine or ionizing radiation, for treating dry mouth disordersUS5548066Dec 2, 1994Aug 20, 1996Central Biomedia, Inc.Failure of passive transfer immune serum and method of making sameUS5603894Oct 31, 1994Feb 18, 1997Abbott LaboratoriesFlowing composition through heat exchanger to sterilize while adjusting temperature and flow rate to minimize degradationUS5609864Jun 8, 1994Mar 11, 1997Shanbrom; EdwardPolyvinylpyrrolidone iodineUS5637451Mar 29, 1995Jun 10, 1997New York Blood Center, Inc.Photodynamic treatment of red blood cells with phthalocyanines and red light at higher light fluence rates is protective of red blood cellsUS5643464Jun 30, 1995Jul 1, 1997Collagen CorporationProcess for preparing a sterile, dry crosslinking agentUS5712086Jun 7, 1995Jan 27, 1998New York Blood Center, Inc.Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactionsUS5730933Apr 16, 1996Mar 24, 1998Depuy Orthopaedics, Inc.Radiation sterilization of biologically active compoundsUS5817528May 16, 1995Oct 6, 1998Therasorb Medizinische Systeme GmbhRemoval substances from bloodUS5837313Jun 13, 1996Nov 17, 1998Schneider (Usa) IncDrug release stent coating processUS5856172Jan 3, 1997Jan 5, 1999Quality Technologies, LlcPreservation of microorganisms in a vial with a cap comprising an immobilized desiccantUS5881534Jun 8, 1995Mar 16, 1999Pharmacia & Upjohn AbProcess for sterilization by radiation and by the use of an oxygen absorber, a container and a medical article sterilized by the processUS5981163Dec 23, 1994Nov 9, 1999New York Blood Center, Inc.Irradiating extracorporeal biological compositions such as blood and blood products in presence of quencher compound(s); deactivates viruses without substantial disruption or deactivation of cells and labile proteinsUS5986168Sep 12, 1997Nov 16, 1999Nicem, Ltd.Prosthesis containing bioabsorbable materials insolubilized without chemical reagents and method of making the sameUS5989498Oct 21, 1996Nov 23, 1999St. Jude Medical, Inc.Crosslinking biological tissue and maintaining in hydrated state; irradiating crosslinked collagen containing tissue with accelerated electron beam for tissues suitable for surgical implantationUS6010719Sep 16, 1997Jan 4, 2000Universiteit GentTherapeutic agent, matrix and binderUS6046024Aug 1, 1997Apr 4, 2000E. R. Squibb & Sons, Inc.Method of producing a fibrin monomer using a biotinylated enzyme and immobilized avidinUS6049025Mar 6, 1998Apr 11, 2000Stone; Kevin R.Removing portion of articular cartilage from a non-human animal to provide xenograft; washing with water and alcohol; subjecting to cellular disruption treatment; digesting wtih glycosidase to remove first surface carbohydrates; cappingUS6060233Apr 15, 1998May 9, 2000Biostore New Zealand, LtdMethods for the lyophilization of platelets, platelet membranes or erythrocytesUS6066626Oct 29, 1998May 23, 2000Genzyme CorporationSupplying active human galactosidase to cellsUS6087141Aug 4, 1998Jul 11, 2000New York Blood Center, Inc.Inactivation of intracellular or extracellular virus within a biocompatible sample; insertion of sample into radiation sensitizer and exposure to ultraviolet radiation or incubate sample with solvent, a detergent or heat treatUS6120592Apr 27, 1998Sep 19, 2000Brault; DenisGamma-radiation crosslinked films from casein and/or its derivatives with plasticizers in controlled amounts, food packagingUS6159490Apr 5, 2000Dec 12, 2000Deghenghi; RomanoPharmaceutical implant for the delivery of an effective amount of a bioactive peptide or peptide analog over a period of 1 to 12 monthsUS6171549Dec 15, 1995Jan 9, 2001Sterisure, Inc.Method for sterilizing productsUS6187572Apr 14, 1993Feb 13, 2001Baxter International Inc.Decontaminating blood and cell cultures by mixing with a chemical radiation sensitizer which does not bind to the membrane, freezing or freeze-drying the mixture, then exposing to electromagnetic radiationUS6190855Oct 28, 1996Feb 20, 2001Baxter International Inc.Systems and methods for removing viral agents from bloodUS6197207May 21, 1997Mar 6, 2001Baxter International Inc.Removing, intact, substantially all leukocytes present in the blood product, or an intermediate of the blood product, prior to administering the blood product to a patient; no significant lysis of the leukocytes to release prionsUS6203544Nov 18, 1998Mar 20, 2001Tutogen Medical, Inc.Fixation elementUS6214534May 24, 1996Apr 10, 2001New York Blood Center, Inc.Deactivator of free radical associations; for the prevention of transfusion-associated graft-versus-host diseaseUS6235508Sep 15, 1998May 22, 2001Baxter International Inc.Mixing virus or cell mixture containing psoralen or coumarin compound with blocking agent like n-acetylcysteine, then irradiating the mixture; reduces ring opening reactionUS6258821Apr 26, 1999Jul 10, 2001Medimmune Oncology, Inc.Compositions comprising trimetrexate and methods of their synthesis and useUS6346216 *May 15, 2000Feb 12, 2002Clearant, Inc.Irradiating biological product at ambient temperature with gamma irradiation at low dose rate for period of time sufficient to sterilize productUSRE23195May 7, 1942Feb 7, 1950 PreservingCA2056619A1Apr 16, 1991Oct 17, 1991Cryopharm CorpMethod of inactivation of viral and bacterial blood contaminantsEP0310316A2Sep 26, 1988Apr 5, 1989Beecham Inc.TGEV-virus of swine as a dog vaccineEP0334679A2Mar 28, 1989Sep 27, 1989National Research Development CorporationImprovements in or relating to the inactivation of infectious agentsEP0919918A2Nov 25, 1998Jun 2, 1999Digital Equipment CorporationApparatus for randomly sampling instructions in a processor pipelineJPH11216147A Title not availableSU1321420A1 * Title not availableWO1990000907A1Jul 20, 1989Feb 8, 1990Univ Salford Business ServicesSterilising methodsWO1991016060A1Apr 16, 1991Oct 31, 1991Cryopharm CorpMethod of inactivation of viral and bacterial blood contaminantsWO1995003071A1Jul 22, 1994Feb 2, 1995Randall S KentMethod for sterilizing productsWO2000025839A1Oct 25, 1999May 11, 2000Norbert KueblerMethod for preparing bone materialWO2001008611A1Jun 21, 2000Feb 8, 2001Tutogen Medical GmbhImplant from osseous materialWO2001012318A1Aug 17, 1999Feb 22, 2001Mobile Process Technology CoRecovery process for oxidation catalyst in the manufacture of aromatic carboxylic acidsWO2001032107A2Oct 30, 2000May 10, 2001Kalas Rolf DieterBone implantWO2001032110A2Oct 30, 2000May 10, 2001Tutogen Medical GmbhImplant consisting of bone materialWO2001045720A1Dec 5, 2000Jun 28, 2001Tutogen Medical GmbhMethod for producing a bone material enriched with bone growth factorsWO2001049219A1Dec 5, 2000Jul 12, 2001Kalas Rolf DieterImplant of bone matterWO2001072233A1Jan 26, 2001Oct 4, 2001Karl KoschatzkyInterference screw made of bone materialWO2001072244A1Jan 29, 2001Oct 4, 2001Tutogen Medical GmbhImplant for cranioplasticsWO2001091818A1Apr 9, 2001Dec 6, 2001Bernd FoehlingerJaw transplant consisting of natural bone material* Cited by examinerNon-Patent CitationsReference1(Abstract of EP0919198A2 and EP0919198A3 (Delphion-DERABS Abstract #G1999-304614)).2"AABB FDA Liaison Meeting," ABC Newsletter, Dec. 12, 1997, p. 14.3A. Ingegneri et al., An 11-Year Assessment of 93 Flash-frozen Homograft Valves in the Aortic Position, 1979, pp. 304-307, Thorac. Cardiovasc. Surgeon, vol. 27.4A. Maeda et al., Effects of Solvent Preservation With or Without Gamma Irradiation on the Material Properties of Canine Tendon Allografts, 1993, pp. 181-189, Journal of Orthopaedic Research, vol. 11.5A.A. Belov et al., The Influence of γ-Radiation on Enzyme Activity of Collalitin in the Process of Storage, Dec. 07, 1989, pp. 519-521, All-Union Research Institute of Textile and Haberdashery Industry, Moscow, engl. abst.6A.D. Kitchen, Effect of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation Proteins, 1989, pp. 223-229, Vox Sang, vol. 56.7A.D. Kitchen, G.F. Mann, J.F. Harrison, A.J. Zuckerman. 1989, Effects of Gamma Irradiation on the Human Immunodeficiency Virus and Human Coagulation Proteins, Box Sanguinis, 56: 223-229.8A.G. Churchalin et al., Clinical Immunosorbents Basing On Space-Network Polymers, 1998, pp. 1524-1529, All Union Research Institute of Chemical Reagents and Chemicals of Special Purity, Moscow, engl. abst.9A.J.J.C. Bogers et al., Long-Term Results of the Gamma-Irradiation-Preserved Homograft Monocusp for Transannular Reconstruction of the Right-Ventricular Outflow Tract in Tetralogy of Fallot, 1994, pp. 337-330, Thorac. Cardiovasc. Surgeon, vol. 42.10A.S. Dagli, Correction of Saddle Nose Deformities by Coral Implantation, 1997, pp. 274-276, Eur. Arch. Otorhinolaryngol, vol. 254.11A.S. Imamaliev et al., Biological Properties of Bone Tisue Conserved in Plastic Material and Sterilized With Gama Rays, 1974, pp. 129-135, ACTA, Chirurgiae Plasticae, vol. 16, No. 3.12AABB FDA Liaison Meeting, ABC Newsletter, Dec. 12, 1997, pp. 14.13Akira Maeda et al., Solvent-dried and Gamma-irradiated Tendon Allografts in Rats, Jul. 1998, pp. 731-736, The Journal of Bone and Joint Surgery, vol. 80-B, No. 4.14Andrezej Komendar et al., Some Biological Properties of Preserved Bovine Fascia Enrighed With Pulverized Calf Cartilage, 1984, pp. 211-219, Archivum Immunologiae et Therapiae Experimentalis, vol. 32.15Andrezej Komender et al., Some Biological Properties of Bovine Trypsinized Fascia Xenografts, 1981, pp. 485-489, Archivum Immunologiae et Therapiae Experimentalis, vol. 29.16B. Horowitz et al., Inactivation of Viruses in Labile Blood Derivatives, II. Physical Methods, 1985, pp. 523-527, Transfusion, vol. 25, No. 6.17Barbara L�ssi-Schlatter et al., Die Antimikrobielle Behandlung von Peroralen Enzympr�paraten mit Gamma-Strahlen, Pharmazeutisches Institut der Eidgen�ssischen Technischen Hochschule Z�rich Galenische Abteilung, english abstract, prior art.18Blanchy, B.B. et al., Immobilization of Factor VIII on Collagen Membranes, J. Biomedical Materials Research, 20:469-479 (1986) (John Wiley & Sons, Inc.).19Boon-Seng Wong et al., Copper Refolding of Prior Protein, 2000, pp. 1217-1224, Biochemical and Biophysical Research Communications, vol. 276.20Boon-Seng Wong et al., Differential Contribution of Superoxide Dismutase Activity by Prior Protein in Vivo, 2000, pp. 136-139, Biochemical and Biophysical Research Communications, vol. 273.21Boon-Seng Wong et al., Prion Disease: A Loss of Antioxidant Function? 2000, pp. 249-252, Biochemical and Biophysical Research Communications, vol. 275.22Borisova, E.A. et al., Protein Degradation During Interphase Death of Thymocytes Induced by Radation and Dexamethasone, pp. 519-521 (1990), abstract.23Boyer, T.D. et al., Radiation Inactivation of Mirosomal Glutathione S-Transferase, The Journal of Biological Chemistry, 261:16963-16968 (1986).24Bradley M. Fideler et al., Effects of Gamma Irradiation on the Human Immunodeficiency Virus, Jul. 1994, The Journal of Bone and Joint Surgery, vol. 76-A, No. 7.25Bradley M. Fideler et al., Gamma Irradiation: Effects on Biomechanical Properties of Human Bone-Patellar Tendon-Bone Allografts, 1995, pp. 643-646, American Journal of Sports Medicine, vol. 23, No. 5.26Brian D. Reid, The Sterways Process: A New Approach to Inactivating Viruses Using Gamma Radiation, 1998, pp. 125-130, Biologicals, vol. 26.27Carol House et al., Inactivation of Viral Agents in Bovine Serum by Gamma Irradiation, 1990 pp. 737-740, Can. J. Microbiol., vol. 36.28Ch. Baquey et al., Radiosterilization of Albuminated Polyester Prostheses, May 1987, pp. 185-189, Biomaterials, vol. 8.29Chanderkar, L.P. et al., Radiation-Induced Changes In Purified Prothrombin and Thrombin, Biochimica et Biophysica Acta, 706:1-8 (1982) (Elsevier Biomedical Press).30Chanderkar, L.P. et al., The Involvement of Aromatic Amino Acids in Biological Activity of Bovine Fibrinogen as Assessed by Gamma-Irradiation, Radiation Research, 65:283-291 (1976) (Academic Press, Inc.).31Chin, S. et al., Virucidal Treatment of Blood Protein Products With UVC Radiation, Photochemistry and Photobiology, 65:432-435 (1997) (American Society for Photobiology).32Cornu, O. et al., Effect of Freeze-Drying and Gamma Irradiation on the Mechanical Properties of Human Cancellous Bone, J. Orthopaedic Research, 18:426-431 (2000).33D. Tylman, Mechanical Character of Liofilized and Sterilized by Gamma-Rays Bone Tissue, 1996, pp. 229-234, Chirurgia Narzadow Ruchu I, Ortopedia Polska, english abstract.34D.A. Haig, Further Studies on the Inactivation of the Scrapie Agent by Ultraviolet Light, 1969, pp. 455-457, J. Gen. Virol., vol. 5.35D.E. Wyatt et al., Is There Life After Irradiation? Part I: Inactivation of Biological Contaminants, Jun. 1993, pp. 34-39, BioPharm.36D.G. Campbell et al., Sterilization of HIV With Irradiation: Relevance to Infected Bone Allografts, 1999, pp. 517-521, Aust. N.Z.J. Surg., vol. 69.37Davey "The Effect of Irradiation on Blood Components" Irradiation of Blood Components, Baldwin et al., eds., Bethesda, MD: American Association of Blood Banks, 1992, pp. 51-62.38David J. Cohen et al., The Fate of Aortic Valve Homografts 12 to 17 Years After Implantation, Mar. 1988, pp. 482-484, Chest, vol. 93, No. 3.39David R. Brown et al., Antioxidant Activity Related to Copper Binding of Native Prion Protein, 2001 pp. 69-76, Journal of Neurochemistry, vol. 76.40David T. Cheung et al., The Effect of γ-Irradiation on Collagen Molecules, Isolated α-chains, and Crosslinked Native Fibers, 1990, pp. 581-589, Journal of Biomedical Materials Research, vol. 24.41Defeng et al. "Sterilization of Silver Acidum Pipemedicum Skin for the Treatment of Burns by Radioactive Cobalt-60-Gamma-Ray" Radiat. Phys. Chem., 1995, pp. 643-646.42Defeng et al., Sterilization of Silver-Acidum Pipemedicum Skin for the Treatment of Burns by Radioactive Cobalt-60-.Gamma.-Ray, 1995, pp. 406 (Abstract).43Donald J. Prolo et al., Composite Autogeneic Human Cranioplasty: Frozen Skull Supplemental With Fresh Iliac Corticocancellous Bone, Dec. 1984, pp. 846-851, Neurosurgery, vol. 15, No. 6.44Donald J. Prolo et al., Superior Osteogenesis in Transplanted Allogeneic Canine Skull Following Chemical Sterilization, Aug. 1982, pp. 230-242, Clinical Orthopaedics and Related Research, No. 168.45Douglas C. Lee et al., A Direct Relationship Between the Partitioning of the Pathogenic Prion Protein and Transmissible Spongiform Encephalopathy Infectivity During the Purification of Plasma Proteins, Apr. 2001, pp. 449-455, Transfusion, vol. 41.46Duane C. Eichler et al., Radiation Inactivation Analysis of Enzymes, Jul. 15, 1987, pp. 9433-9436, The Journal of Biological Chemistry, vol. 262, No. 20.47Dyskin, E.A. et al., Hemomicrocirculatory Bed in the Wall of Hollow Organs of the Dog Gastrointestinal Tract at Portal Hypertension, Arkh Anat Gistol Embiol, 93:58-68 (1987).48Dziedzic-Goclawska, A. et al., Effect of Radiation Sterilization on the Osteoinductive Properties and the Rate of Remodeling of Bone Implants Preserved by Lyophilization and Deep-Freezing, Clinical Orthopaedics and Related Research, 272:30-37 (1991).49E.S. Kempner et al., Size Determination of Enzymes by Radiation Inactivation, 1979, pp. 2-10, Analytical Biochemistry, vol. 92.50Edward A. Rittenhouse et al., Sterilization of Aortic Valve Grafts for Transplantation, Jul. 1970, pp. 1-5, Aortic Valve Grafts for Transplantation, Archives of Surgery, vol. 101, No. 1.51Edward H. Bedrossian, Jr., HIV and Banked Fascia Lata, 1991, pp. 284-288, Ophthalmic Plastic and Reconstructive Surgery, vol. 7, No. 4.52Elena Quaglio et al., Copper Converts the Cellular Prion Protein Into a Protease-resistant Species That Is Distinct From the Scrapie Isoform, Apr. 6, 2001, pp. 11432-11438, The Journal of Biological Chemistry, vol. 276, No. 14.53Ernest U. Conrad et al., Transmission of the Hepatitis-C Virus by Tissue Transplantation, Feb. 1995, pp. 214-224, The Journal of Bone and Joint Surgery, vol. 77-A, No. 2.54F.W. Hehrlein et al., Biochemische Ver�anderungen an Heterologen Aortenklappentransplantaten nach Anwendung Verschiedener Sterilisationsverfahren, pp. 1183-1185, Langenbecks Arch. Chir., Bd. 325 (Kongrebericht) (English Summary found at page (1183).55F.W. Hehrlein et al., Morphologische Utersuchungen an Heterologen Herzklappentransplantaten Unter Verschiedenen Sterilisationsbedingungen, pp. 244-251 (English Summary found at p. 250), prior art.56Fields et al., Susceptibility of Scrapie Agent to Ionizing Radiation, Apr. 5, 1969, pp. 90-91, Nature, vol. 222.57G. Campalani et al., Aortic Valve Replacement With Frozen Irradiated Homografts, 1989, pp. 558-561, Eur. J. Cardio-thoracic Surgery, vol. 3.58G.A. Yarygina, Dose Rate Effect on Survival of Microorganisms Used As Test-Cultures in Radiation Sterilization of Medical Products, 1973, pp. 32-39, Radiats. Tekh., No. 9 (Abstract).59G.L. Moore et al., Effects of 4000 Rad. Irradiation on the In Vitro Storage Properties of packed Red Cells, Nov.-Dec. 1985, pp. 583-585, Final Rept., Pub. In Transfusion, vol. 25, No. 6 (Abstract).60Ghosh, M.M. et al., A Comparison of Methodologies for the Preparation of Human Epidermal-Dermal Composites, Annals of Plastic Surgery; 39:390-404 (1997) (Lippincott-Raven Publishers).61Guy Beauregard et al., Temperature Dependence of the Radiation Inactivation of Proteins, 1985, pp. 117-120, Analytical Biochemistry, vol. 150.62H. Hiemstra et al., Inactivation of Human Immunodeficiency Virus by Gamma Radiation and its Effect on Plasma and Coagulation Factors, 1991, pp. 32-39, Transfusion, vol. 31, No. 1.63H. Sato et al., Sterilization of Therapeutic Immunoadsorbents by Ionizing Radiation, 1986, pp. 131-136, The International Journal of Artificial Organs, vol. 9, No. 2.64Hsing-Wen Sung et al., Effects of Various Chemical Sterilization Methods on the Crosslinking and and Enzymatic Degradation Characteristics of an Epoxy-Fixed Biological Tissue, Dec. 1996, pp. 376-383, Sterilization of Biological Tissues.65Hsiue, G. et al., Absorbable Sandwich-Like Membrane for Retinal-Sheet Transplantation, pp. 20-25 (2002 (Wiley Periodicals, Inc).66J. Baksa et al., The Use of Pig's Skin (xenograft) for the Treatment of Burns, 1976, pp. 138-145, Magyar Traumatologin, vol. 19, english abstract.67J. Jerosch et al., A New Technique for Bone Sterilization, 1989, pp. 117-120, Biomedizinische Technik, Band 34, Heft 5.68J. Jerosch et al., Influence of Different Rehydration Periods on the Stability and the Water Content of Bone Allografts After Lyophilization, Gamma-Irradiation, and Lipid Extraction, 1994, pp. 335-341, Z. Orthop., vol. 132, engl. abst.69J.D. Keathley et al., Is There Life After Irradiation? Part 2: Gamma-Irradiated FBS in Cell Culture Jul./Aug. 1993, pp. 46-52, BioPharm.70J.F. Kouvalchouk et al., The Use of Sterilized Bone Allografts in Reconstruction After Tumour Resection, 1986, pp. 393-401, Revue de Chirurgie Orthopedique, vol. 72, english abstract.71J.M. White et al., Sterilization of Teeth by Gamma Radiation, Sep. 1994, pp. 1560-1567, J. Dent. Res., vol. 73, No. 9.72J.R.P. Gibbons et al., Effects of Gamma Irradiation on the Initial Mechanical and Material Properties of Goat Bone-Patellar Tendon-Bone Allografts, 1991, pp. 209-218, J. Orthop Res, vol. 9, No. 2.73J.R.P. Gibbons et al., Gamma Ray Sterilisation of Homograft Valves, 1969, pp. 353-358, Bulletin De La Societe Internationale De Chirugie, No. 3.74James R. Malm et al., An Evaluation of Aortic Valve Homografts Sterilized by Electron Beam Energy, Oct. 1967, pp. 471-477, Journal of Thoracic and Cardiovascular Surgery, vol. 54, No. 4.75James R. Malm et al., Results of Aortic Valve Replacement Utilizing Irradiated Valve Homografts, pp. 740-747, Annals New York Academy of Sciences, prior art.76Jan Parizek et al., Duraplasty With Pretreated Freeze-Dried Sterilized Human Dura Mater, 1990, pp. 135-143, Sbor. ved. Praci LF UK Hradee Kralove, vol. 33, english abstract.77Jan Parizek et al., Ovine Pericardium: A New Material For Duraplasty, 1996, pp. 508-513, J. Neurosurg., vol. 84.78Jensen, J. et al., Membrane-bound Na, K-ATPase: Target Size and Radiation Inactivation Size of Some of Its Enaymatic Reactions, J. Biological Chemistry, 263:18063-18070 (1988) (Am. Soc. for Biochem. and Mol. Biol.).79Jensen, O. T. et al., Vertical Guided Bone-Graft Augmentation in a New Canine Mandibular Model, The Int'l Journal of Oral and Maxillofacial Implants, 10:335-343 (1995).80K. Pietrucha, New Collagen Implant As Dural Substitute, Apr. 1991, pp. 320-323, Biomaterials, vol. 12.81Kamat, H.N. et al., Correlation of Structrual Alterations in Bovine Fibrinogen with Loss of Clotting Properties After Gamma Irradiation, Radiation Research, 49:381-389 (1972) (Academic Press, Inc.).82Katz, R.W. et al., Radiation -Sterilized Insoluble Collagenous Bone Matrix is a Functional Carrier of Ostgeogenin for Bone Induction, Calcified Tissue Int., 47:183-185 (1990) (Springer-Verlag New York Inc.).83Kempner, E.S. et al., Effect of Environmental Conditions on Radiation Target Size Analyses, Analytical Biochemistry, 216:451-455 (1994).84Kempner, E.S. et al., Radiation-Damaged Tyrosinase Molecules are Inactive, Biophysical Journal, 55:159-162 (1989) (Biophysical Society).85Ken Nakata et al., Reconstruction of the Lateral Ligaments of the Ankle Using Solvent-dried and Gamma-Irradiated Allogeneic Fascia Lata, May 2000, pp. 579-582.86Kuijpers, A.J. et al. In vivo Compatibility and Degradation of Crosslinked Gelatin Gels Incorporated in Knitted Dacron, pp. 137-144 (2000) (John Wiley & Sons, Inc.).87L. Callegaro et al., Hollow Fiber Immobilized L-Asparaginase: In Vivo and In Vitro Immunological Studies, 1983, pp. 91-96, The International Journal of Artificial Organs, vol. 6, No. 2.88L. Kerboull et al., In Vitro Study of the Influence of Avrious Conservation Methods on the Mechanical Properties of Patellar Tendon Allografts, 1991, pp. 751-762, Chirurgie, vol. 117, english abstract.89L.V. Polezhaeu et al., Repair of Cranial Defects With Regenerating Bone in Grafting Gamma-Irradiated Bone Filings, pp. 57-60.90Le Maire, M. et al., Effects of Ionizing Radiations on Proteins, Journal of Biochem., 267:431-439 (1990).91Leitman, "Use of Blood Cell Irradiation in the Prevention of Posttransfusion Graft-vs-Host Disease" Transfus. Sci., vol. 10, No. 3, 1989, pp. 219-232.92License Amendment and procedures for Gamma Irradiation of Blood Products, Jun. 22, 1993, pp. 1-18, Dept. of Health & Human Services, Food and Drug Administration.93Linberg et al., Irradiated Homologous Cartilage For Orbital Reconstruction, Jul. 1980, pp. 457-462, Ophthalmic Surgery, vol. 11.94Linda Marton et al., Disinfection and Inactivation of the Human T. Lymphotrogic Virus Type III/Lymphadenopathy-Associated Virus, Aug. 1985, pp. 499-403, The Journal of Infectious Diseases, vol. 151, No. 2.95Liu Bingci, Mouse Antibody Response Following Repetitive Injections of Gamma-Irradiated Human Placenta Collagen, Jun. 1994, pp. 100-103, Chinese Medical Sciences Journal, vol. 9, No. 2.96Luanne H. Elliott et al., Inactivation of Lassa, Marburg and Ebola Viruses by Gamma Irradiation, Oct. 1982, pp. 704-708, Journal of Clinical Microbiology, vol. 16, No. 4.97M. Horowitz, Sterilization of Homograft Ossicles by Gamma Radiation, Nov. 1979, pp. 1087-1089, The Journal of Laryngology and Otology, vol. 93.98M.F. Alladine et al., γ-Radiation Damage to Starr-Edwards Valves, Mar. 16, 1998, pp. 68, The Lancet, Letters to the Editor.99M.J. Goertzen et al., Anterior Cruciate Ligament Reconstruction Using Cryopreserved Irradiated Bone-ACL-Bone-Allograft Transplants, 1994, pp. 150-157, Knee Surgery Sports Traumatology Arthroscopy, vol. 2.100M.J. Goertzen et al., Sterilisation of Canine Anterior Cruciate Allografts by Gamma Irradiation in Argon, Mar. 1995, pp. 205-212, The Journal of Bone and Joint Surgery, vol. 77-B, No. 2.101Ma, J.T. et al., Functional Size Analysis of F-ATPase from Escherichia coli by Radiation Inactivation, The Journal of Biological Chemistry, 268:10802-10807 (1993) (The Am. Soc. for Biochem. and Mol. Bio., Inc.).102Maria Esther Martinez Pardo et al., Clinical Application of Amniotic Membranes on a Patient With Epidermolysis Bullosa, 1999, pp. 68-73, Annals of Transplantation, vol. 4, No. 3-4.103Maria Raptopoulou-Gigi et al., Antimicrobial Proteins in Sterilised Human Milk, Jan. 1, 1977, pp. 12-14, British Medical Journal, vol. 1.104Martindale's Extra Pharmacopoecia, Glucose p. 1265; prior art.105Martindale's Extra Pharmacopoecia, Glucose, p. 1265; prior art.106Marx, G. Protecting Fibrinogen with Rutin During UVC Irradiation for Viral Inactivation, Photochemistry and Photobiology, 63:541-546 (1996) (American Society for Photobiology).107Michael L. Baldwin et al., Irradiation of Blood Components, 1992, pp. 10-78, American Association of Blood Banks.108Munting, E. et al., Effect of Sterilization on Osteoinduction, Acta Orthop. Scand., 59:34-38 (1988).109Nagrani, S. et al., The Radiation-Induced Inactivation of External Yeast Invertase in Dilute Aqueous Solution, Int. J. Radiat. Biol., 55:191-200 (1989) (Taylor & Francis Ltd.).110Nielsen, M. et al., The Apparent Target Size of Rat Brain Benzodiazepine Receptor, Acetylcholinesterase, and Pyruvate Kinase Is Highly Influenced by Experimental Conditions, The Journal of Biological Chemistry, 263:11900-11906 (1988) (The American Society for Biochemistry and Molecular Biology, Inc.).111Ozan Akkus et al., Fracture Resistance of Gamma Radiation Sterilized Cortical Bone Allografts, 2001, pp. 927-934, Journal of Orthopaedic Research, vol. 19.112P. Brown et al., Further Studies of Blood Infectivity in an Experimental Model of Transmissible Spongiform Encephalopathy, With an Explanation of Why Blood Components Do Not Transmit Creutzfeldt-Jakob Disease in Humans, Nov./Dec. 1999, pp. 1169-1178, Transfusion, vol. 39.113P. Brown et al., The Distribution of Infectivity in Blood Components and Plasma Derivatives in Experimental Models of Transmissible Spongiform Encephalopathy, Sep. 1998, pp. 810-816, Transfusion, vol. 38.114P. Brown, The Risk of Blood-Borne Creutzfeldt-Jakob Disease, 1999, pp. 53-59, Advances in Transfusion Safety Dev. Biol. vol. 102.115P. De Deyne et al., Some Effects of Gamma Irradiation on Patellar Tendon Allografts, 1991, pp. 51-62, Connective Tissue Research, vol. 27.116P. Di Simplicio et al., The Reactivity of the SH Group of Bovine Serum Albumin With Free Radicals, 1991, pp. 253-262, Free Rad. Res. Comms., vol. 14, No. 4.117 *Patel et al. "Effect of gamma radiation and ethylene oxide on papain," Indian J. Pharm. Sci. (1979), 41(2), pp. 81-83.*118Paul Brown et al., Effect of Chemicals, Heat, and Histopathologic Processing on High-Infectivity Hamster-Adapted Scrapie Virus, May 1982, pp. 683-687, The Journal of Infectious Diseases, vol. 145, No. 5.119Ph. Hernigou et al., Radiation Sterilization of Bone and the HIV Virus, 1993, pp. 445-451, Revue de Chirurgie Orthopedique, vol. 79, english abstract.120Plavsic, Z. M. et al., Resistance of Porcine Circovirus to Gamma Irradation, BioPharm, pp. 32-36 (Apr. 2001).121Pollard, The Effect of Ionizing Radiation on Viruses, pp. 65-71.122Potier, M. et al., Radiation Inactivation of Proteins: Temperature-Dependent Inter-Protomeric Energy Transfer in Ox Liver Catalase, Biochem. J., 298:571-574 (1994).123Prolo, D.J. et al., Composite Autogeneic Human Cranioplasty: Frozen Skull Supplemented With Fresh Iliac Corticocancellous Bone, Neurosurgery, 15:846-851 (1984) (The Congress of Neurological Surgeons).124Puolakkainen, P.A. et al., The Effect of Sterilization on Transforming Growth Factor beta Isolated From Demineralized Human Bone, Transfusion, 33:679-685 (1993).125Puolakkainen, P.A. et al., The Effect of Sterilization on Transforming Growth Factor β Isolated From Demineralized Human Bone, Transfusion, 33:679-685 (1993).126Qi Zhang et al., Ethylene Oxide Does Not Extinguish the Osteoinductive Capacity of Demineralized Bone, 1997, pp. 104-108, Acta Orthop Scand, vol. 68, No. 2.127R. Guidoin et al., A Compound Arterial Prosthesis: The Importance of the Sterilization Procedure on the Healing and Stability of Albuminated Polyester Grafts, Mar. 1985, pp. 122-128, Biomaterials, vol. 6.128R. Latarjet et al., Inactivation of the Scrapie Agent by Near Monochromatic Ultraviolet Light, Sep. 26, 1970, pp. 1341-1343, Nature, vol. 227.129R.G. Burwell, The Fate of Freeze-Dried Bone Allografts, Jun. 1976, pp. 95-111, Transplantation Proceedings, vol. VII, No. 2, Supplement 1.130R.G. Rohwer, The Scrapie Agent: A Virus by Any Other Name, pp. 195-232, Current Topics in Microbiology and Immunology, vol. 172.131R.H. Bassin et al., Abrogation of Fv-1<b>Restriction With Murine Leukemia Viruses Inactivated by Heat or by Gamma Irradiation, May 1978, pp. 306-315, Journal of Virology, vol. 26, No. 2.132R.H. Bassin et al., Abrogation of Fv-1bRestriction With Murine Leukemia Viruses Inactivated by Heat or by Gamma Irradiation, May 1978, pp. 306-315, Journal of Virology, vol. 26, No. 2.133R.I. Vaida et al., Structural-Functional Peculiarities of Myocardial Capillaries After Resection of the Lungs, Oct. 21, 1986, pp. 68-73, english abstract.134R.J. Donnelly et al., Gamma-radiation of Heart Valves at 4� C; A Comparative Study Using Techniques of Histochemistry and Electron and Light Microscopy, 1973, pp. 95-101, Thorax, vol. 28.135Raymond Latarjet, Inactivation of the Agents of Scrapie, Creutzfeldt-Jakob Disease, and Kuru by Radiations, 1979, pp. 387-407, Slow Transmissible Diseases of the Nervous System, vol. 2.136Richard A. Smith et al., Gamma Irradiation of HIV-1, 2001, pp. 815-819, Journal of Orthopaedic Research, vol. 19.137Richard Hinton et al., A Biomechanical Analysis of Solvent-dehydrated and Freeze-Dried Human Fascia Lata Allografts, 1992, pp. 607-612, The American Journal of Sports Medicine, vol. 20, No. 5.138Ripamonti, U. et al., Long-Term Evaluation of Bone Formation by Osteogenic Protein 1 in the Baboon and Relative Efficacy of Bone-Derived Bone Morphogenetic Proteins Delivered by Irradiated Xenogeneic Collagenous Matrices, J. Bone and Mineral Research, 15:1798-1809 (2000) (Am. Soc. for Bone and Mineral Res.).139Robert G. Rohwer et al., Scrapie-Virus or Viroid, The Case For A Virus, pp. 333-355, Laboratory of Central Nervous System Studies, National Institutes of Neurological and Communicative Disorders and Stroke, National Institutes of Health.140Robert G. Rohwer, Estimation of Scrapie Nucleic Acid MW From Standard Curves for Virus Sensitivity to Ionizing Radiation, Mar. 27, 1986, pp. 381, Nature, vol. 320, No. 6060.141Robert G. Rohwer, Scrapie Infectious Agent is Virus-like in Size and Susceptibility to Inactivation, Apr. 12, 1984, pp. 658-662, Nature, vol. 308.142Robert G. Rohwer, Virus-Like Sensitivity of the Scrapie Agent to Heat Inactivation, Feb. 10, 1984, pp. 600-602, Science, vol. 223.143Robert Sullivan et al., Inactivation of Thirty Viruses by Gamma Radiation, Jul. 1971, pp. 61-65, Applied Microbiology, vol. 22, No. 1.144S. Malawski et al., The Use of Dry-Freezed Bone Grafs Sterilized by Gamma Rays in Orthopaedic Surgery, 1969, pp. 61-68, Chir. Narz. Ruchu Ortop, english abstract.145S.C. Roe et al., The Effect of Gamma Irradiation on a Xenograft Tendon Bioprothesis, 1992, pp. 149-154, Clinical Materials, vol. 9.146S.I. Miekka et al., New Methods for Inactivation of Lipid-enveloped and Non-enveloped Viruses, 1998, pp. 402-408, Haemophilia, vol. 4.147S.R. Aparicio et al., Light and Electron Microscopy Studies on Homograft and Heterograft Heart Valves, 1975, pp. 174-162, J. Path, vol. 115.148Sakai, T. et al., Microbiological Studies on Drugs and Their Raw Materials. IV. Sterilization of Microbial Contaminants in Enzyme Powder by Gamma Irradiation, Chem. Pharm. Bull., 26:1130-1134 (1987).149Salehpour, A. et al., Dose-Dependent Response of Gamma Irradiation on Mechanical Properties and Related Biochemical Composition of Goat Bone-Patellar Tendon-Bone Allografts, J. Orthopaedic Research, 13:898-906 (1995).150Salim-Hanna, M. et al., Free Radical Scavenging Activity Of Carnosine, Free Rad. Res. Comms., 14:263-270 (1991) (Harwood Academic Publishers GmbH).151Sandra Blakeslee, Tight Rules on Use of Organs Do Not Apply to Tissues, Jan. 20, 2002. The New York Times Newspaper.152Sandra McDowell, Irradiated Cartilage, Spring 1988, pp. 14-15, Plastic Surgical Nursing.153Schwarz, N. et al., Irradiation-sterilization of Rat Bone Matrix Gelatin, Acta Orthop Scand, 59:165-167 (1988).154Seymour S. Block, Disinfection, Sterilization, and Preservation, Fundamental Principles of Activity Principles of Antimicrobial Activity, Fourth Edition, 1991, pp. 31-33.155Shcheglova et al., The Effect of the Power of Gamma-Radiation on the Radiation Dose in the Sterilization of Drugs, 1984, pp. 730-732, Khim-Farm Zh, vol. 18, No. 6 (Abstract).156Shinichiro Ijiri et al., Effect of Sterilization on Bone Morphogenetic Protein, 1994, pp. 628-636, Journal of Orthopaedic Research, vol. 12.157Slawomir Gregorczyn et al., Strength of Lyophilized and Irradiated Cortical Bone of the Human Femur, 1995, pp. 129-133, Chir. Narz. Ruchu Ortop. Pol., Lx 2, english abstract.158Smith, C.W. et al., Mechanical Properties of Tendons: Changes With Sterilization and Preservation, J. Biomechanical Engineering, 118:56-61 (1996) (ASME).159Song, K.B. et al., Effect of Gamma-irradiation on the Physicochemical Properties of Blood Plasma Proteins, 2002 Annual Meeting and Food Expo-Anaheim, California, Session 30C-1, Food and Chemistry: Proteins, (Jun. 2002) (Abstract).160Suomela, H., Inactivation of Viruses in Blood and Plasma Products, Transfusion Medicine Reviews, 7:42-57 (1993) (W.B. Saunders Company).161Susan F. Leitman, Use of Blood Cell Irradiation in the Prevention of Posttransfusion Graft-vs-Host Disease, 1989, pp. 219-232, Transfus. Sci., vol. 10.162T.J. Rasmussen et al., The Effects of a 4 Mrad of Gamma-Irradiation on the Initial Mechanical Properties of Bone-Patellar Tendon-Bone Grafts, 1994, pp. 188-197, The Journal of Arthroscoic and Related Surgery, vol. 10, No. 2.163The Merck Index, Eleventh Edition Glucose pp. 4353-4354, prior art.164Tikvah Alper et al., Does the Agent of Scrapie Replicate Without Nucleic Acid? May 20, 1967, pp. 764-766, Nature, vol. 214.165Tikvah Alper et al., Protection by Anoxia of the Scrapie Agent and Some DNA and RNA Viruses Irradiated as Dry Preparations, 1968, pp. 157-166, J. Gen. Virol., vol. 3.166Tikvah Alper et al., The Exceptionally Small Size of the Scrapie Agent, 1966, pp. 278-284, Biochemical and Biophysical Research Communications, vol. 22, No. 3.167Tikvah Alper et al., The Scrapie Agent: Evidence Against its Dependence For Replication on Intrinsic Nucleic Acid, 1978, pp. 503-516, J. Gen. Virol., vol. 41.168Toritsuka, Y . et al., Effect of Freeze-Drying or gamma-Irradiation on Remodeling of Tendon Allograft in Rat Model, J. Orthopaedic Research, 15:294-300 (1997) (Orthopaedic Research Society).169Toritsuka, Y . et al., Effect of Freeze-Drying or γ-Irradiation on Remodeling of Tendon Allograft in Rat Model, J. Orthopaedic Research, 15:294-300 (1997) (Orthopaedic Research Society).170W. Oh et al., Mitral Valve Replacement With Preserved Cadaveric Aortic Homografts, May 1973, pp. 712-721, The Journal of Thoracic and Cardiovascular Surgery, vol. 65, No. 5.171W. Welch, A Comparative Study of Different Methods of Processing Aortic Homografts, 1969, pp. 746-749, Thorax, vol. 24.172Wangerin, K., et al., Behavior of Differently Sterilized Allogenic Lyophilized Cartilage Implants in Dogs, J. Oral Maxillofac Surg., 45:236-242 (1987).173Website: www.benvue.com/history/history_content.html, (2002).174Website: www.phase-technologies.com/html/vol.1no10.html , Jennings, T.A., (Yes, You have no Eutectic) (1998), abstract.175Website: www.phase-technologies.com/html/vol.1no2.html , Jennings, T.A., (Role of Product Temperature in the Lyophilization Process) (1988), abstract.176Website: www.phase-technologies.com/html/vol.1no7.html , Jennings, T.A., (Which Shelf Temperature During Lyophilization?) (1998), abstract.177Website: www.phase-technologies.com/html/vol.1no9.html , Jennings, T.A., (Overview of the Lyophilization Process) (1998), abstract.178Website: www.phase-technologies.com/html/vol.2no1.html , Jennings, T.A., (Glossary of Terms for Lyophilization) (1999), abstract.179Website: www.phase-technologies.com/html/vol.2no2.html , Jennings, T.A., (What I Wish I Knew About Lyophilization) (1999), abstract.180Website: www.usacc.org/ataccc/ppt.html, (Advanced Technology Applications for Combat Casualty Care, 2001 Presentations, US Army Medical Research and Material Command Combat Casualty Care Research Program (2001)).181Website: www.usacc.org/RevisedStepB.html, Bakaltcheva, I. et al., (FY01 Request for Proposals-Intramural-Revised 2, Combat Casualty Care Research Program, (2002)).182Website: www.wslfweb.org/docs/dstp2000.dtopdf/19-MD.pdf (Defense Science and Technology Plans, (Feb. 2000) p. 176, Section II, MD.03, U.S. Department of Defense Deputy Under Secretary of Defense (Science and Technology)).183Wientroub, S. et al., Influence of Irradiation on the Osteoinductive Potential of Demineralilzed Bone Matrix, Calcified Tissue International, 42:255-260 (1988) (Springer-Verlag New York Inc.).184Wyatt et al., "Is There Life After Irradiation? Part 1: Inactivation of Biological Contaminants," Bio. Pharm., Jun. 1993, pp. 34-39.185Wyatt et al., "Is There Life After Irradiation? Part 2: Inactivation of Biological Contaminants," Bio. Pharm., Jul.-Aug. 1993, pp. 46-52.186Yongxing Zhang et al., A Comprehensive Study of Physical Parameters, Biomechanical Properties and Statistical Correlations of Iliac Crest Bone Wedges Used in Spinal Fusion Surgery, 1994, pp. 304-308, Spine, vol. 19, No. 3.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS7252799 *Aug 31, 2001Aug 7, 2007Clearant, Inc.Methods for sterilizing preparations containing albuminUS7704453Jun 7, 2007Apr 27, 2010Ethicon, Inc.Method for establishing a sterilizing dose for radiation sensitive productsUS8409499Mar 11, 2010Apr 2, 2013Ethicon, Inc.Method for establishing a sterilizing dose for radiation sensitive productsUS8580192Oct 31, 2006Nov 12, 2013Ethicon, Inc.Sterilization of polymeric materialsUS8585965Nov 26, 2012Nov 19, 2013Ethicon, Inc.Sterilization of polymeric materialsCN1298227C *Dec 30, 2004Feb 7, 2007上海三生生物技术有限公司Effective sterilizing method capable of keeping colostrum immune globulin activity* Cited by examinerClassifications U.S. Classification422/22, 435/2International ClassificationA61L2/00, A61L2/08Cooperative ClassificationA61L2202/22, A61L2/0029, A61L2/0035, A61L2/0076European ClassificationA61L2/00P2R2Legal EventsDateCodeEventDescriptionDec 13, 2011FPExpired due to failure to pay maintenance feeEffective date: 20111021Oct 21, 2011LAPSLapse for failure to pay maintenance feesMay 30, 2011REMIMaintenance fee reminder mailedApr 30, 2007SULPSurcharge for late paymentApr 30, 2007FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google